| Literature DB >> 35935328 |
Zhongwei Li1, Di Wang2, Jinfeng Sun3, Guowei Zhang1, Jiashou Hu2.
Abstract
The aim of this study was to evaluate the value of whole body magnetic resonance diffusion-weighted imaging (WB-DWI) combined with routine scanning in the diagnosis of body tumors. Sixty-three patients with surgically and pathologically confirmed body tumors admitted to our hospital from October 2019 to October 2021 were scanned by WB-DWI using a 1.5TMR body coil. The images were reconstructed by a three-dimensional maximum intensity projection (3D-MIP) and black-white inversion technique. The lesions detected by WB-DWI were all plain MRI, and 35 cases were enhanced MRI. The number of lesions detected by WB-DWI and WB-DWI combined with routine scanning and the number of cases matching diagnosis were compared. The WB-DWI images of tumor lesions were analyzed, and the apparent diffusion coefficient (ADC) of the lesions was measured, and the ADC value of benign and malignant lesions was compared. There were 236 lesions in 63 patients with clinically confirmed tumors. 46 cases were diagnosed by WB-DWI, the diagnostic coincidence rate was 73.0%, and 207 lesions were detected. Fifty-eight cases were diagnosed by WB-DWI combined with routine scanning, the diagnostic coincidence rate was 92.1%, 236 lesions were detected. There were statistically significant differences in the number of lesions detected and the coincidence rate of tumor diagnosis between the two groups (P < 0.05). The average ADC value of malignant tumor ((1.04 ± 0.46) × 10-3 mm2/s) was lower than that of benign tumor ((2.53 ± 0.43) × 10-3 mm2/s), and the difference was statistically significant (P < 0.05). In conclusion, MR whole-body diffusion weighted imaging is safe, efficient, radiation-free, and highly sensitive, which is of great significance in the differential diagnosis of benign and malignant lesions. WB-DWI combined with MR routine scanning can further improve the detection rate of lesions and the coincidence rate of tumor diagnosis.Entities:
Mesh:
Year: 2022 PMID: 35935328 PMCID: PMC9334083 DOI: 10.1155/2022/5799815
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
Type, metastasis and number of tumors.
| Tumor type combined metastatic site | The number of cases |
|---|---|
| Nasopharyngeal carcinoma | 3 |
| | 1 |
| Lung cancer | 13 |
| | 8 |
| | 2 |
| | 1 |
| Hepatocellular carcinoma | 6 |
| | 2 |
| Pancreatic cancer | 4 |
| | 2 |
| Kidney cancer | 5 |
| | 1 |
| | 2 |
| Prostate cancer | 4 |
| | 1 |
| Lymphoma | 5 |
| Hepatic hemangioma | 15 |
| Renal eosinophil tumor | 1 |
| Adrenal myelolipoma | 1 |
| Ovarian teratoma | 1 |
| Uterine fibroids | 5 |
Figure 1Kidney cancer. (a) WB-DWI image showed a significant low signal shadow in the right kidney with a range of 5.3 cm × 4.4 cm. (b) T1WI showed the lesion with low signal. (c) Lipid-suppressed T2WI showed hyperintense lesions with well-defined edges and areas of liquefaction necrosis. (d) Gd-DTPA dynamic enhanced scanning in arterial phase, the solid part of the lesion was significantly enhanced with clear boundary. (e) Lesion enhancement decreased during the coronal equilibrium phase.
Figure 2Adrenal myelolipoma. (a) WB-DWI image showed patchy low signal shadow in the left adrenal area. (b) Fat suppression T2WI showed a 2.2 cm × 2.9 cm oval lesion in the left adrenal gland, with clear edge, slightly high signal, and uneven signal. (c) Positive phase diagram of T1WI double echo sequence showed isosignal of the lesion. (d) Inverse phase diagram of double echo sequence showed that the signal of the lesion is significantly reduced.
Comparison of the number of lesions detected by WB-DWI and WB-DWI combined with routine scanning and the ADC value of tumor lesions (×10−3 mm2/s) (b = 600 s/mm2).
| Tumor type | The number of lesions detected by WB-DWI combined with routine scan | The number of lesions detected by WB-DWI | The average ADC values |
|---|---|---|---|
| Nasopharyngeal carcinoma | 3 | 3 | 0.92 ± 0.41 |
| Lung cancer | 13 | 10 | 1.38 ± 0.48 |
| Hepatocellular carcinoma | 6 | 6 | 1.21 ± 0.29 |
| Liver metastases | 28 | 17 | 1.19 ± 0.52 |
| Pancreatic cancer | 4 | 4 | 1.48 ± 0.65 |
| Kidney cancer | 5 | 3 | 2.42 ± 0.33 |
| Prostate cancer | 4 | 3 | 1.26 ± 0.57 |
| Lymphoma | 17 | 17 | 0.97 ± 0.69 |
| Metastatic lymph node | 43 | 43 | 0.93 ± 0.31 |
| Bone metastases | 69 | 69 | 0.85 ± 0.53 |
| Hepatic hemangioma | 34 | 26 | 2.73 ± 0.41 |
| Renal eosinophil tumor | 1 | 1 | 2.63 |
| Adrenal myelolipoma | 1 | 1 | 2.45 |
| Ovarian teratoma | 1 | 1 | 1.59 |
| Uterine fibroids | 7 | 3 | 2.01 ± 0.35 |
Diagnostic comparison of 63 patients with WB-DWI and WB-DWI combined with MRI routine scanning.
| Diagnostic methods | Benign tumor | Malignant tumor | Tumor diagnosis coincidence rate |
|---|---|---|---|
| WB-DWI scanning | 16 | 30 | 73.0% |
| WB-DWI combined with MRI routine scanning | 22 | 36 | 92.1% |
|
| 0.109 | ||
|
| 0.048 |
Comparison of ADC values of benign and malignant tumors in body (×10−3 mm2/s).
| Tumor types | Number of lesions | Maximum average ADC value | Minimum average ADC value | Average ADC values |
|---|---|---|---|---|
| Benign tumor | 32 | 2.67 ± 0.49 | 1.59 ± 0.38 | 2.53 ± 0.43 |
| Malignant tumor | 175 | 2.46 ± 0.38 | 0.87 ± 0.46 | 1.04 ± 0.46 |
|
| 2.74 | 8.34 | 17.01 | |
|
| 0.01 | <0.001 | <0.001 |